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Abstract
Background: Incidence rates are fundamental to epidemiology, but their magnitude and interpretation depend on
methodological choices. We aimed to examine the extent to which the definition of the study population affects
cancer incidence rates.
Methods: All primary cancer diagnoses in Sweden between 1958 and 2010 were identified from the national
Cancer Register. Age-standardized and age-specific incidence rates of 29 cancer subtypes between 2000 and 2010
were calculated using four definitions of the study population: persons resident in Sweden 1) based on general
population statistics; 2) with no previous subtype-specific cancer diagnosis; 3) with no previous cancer diagnosis
except non-melanoma skin cancer; and 4) with no previous cancer diagnosis of any type. We calculated absolute
and relative differences between methods.
Results: Age-standardized incidence rates calculated using general population statistics ranged from 6% lower
(prostate cancer, incidence rate difference: -13.5/100,000 person-years) to 8% higher (breast cancer in women,
incidence rate difference: 10.5/100,000 person-years) than incidence rates based on individuals with no previous
subtype-specific cancer diagnosis. Age-standardized incidence rates in persons with no previous cancer of any type
were up to 10% lower (bladder cancer in women) than rates in those with no previous subtype-specific cancer
diagnosis; however, absolute differences were <5/100,000 person-years for all cancer subtypes.
Conclusions: For some cancer subtypes incidence rates vary depending on the definition of the study population.
For these subtypes, standardized incidence ratios calculated using general population statistics could be misleading.
Moreover, etiological arguments should be used to inform methodological choices during study design.
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Background
Incidence rates are fundamental to descriptive epidemi-
ology for quantifying disease occurrence in populations,
and to analytical epidemiology for comparing disease oc-
currence according to exposure status [1]. They are cal-
culated simply as the number of new cases of disease
per unit of person-time at risk of becoming a case. How-
ever, calculating incidence rates for cancer is more com-
plex, since one individual may have multiple primary
cancer diagnoses over time. How to handle multiple
cancers is a common design issue to be considered in
any cohort study.
Cancer registries often calculate incidence rates based
on aggregate general population statistics, i.e., the total
number of new primary tumors recorded each year divided
by the mean population that year, regardless of previous
cancer diagnoses and exact person-time accumulated [2, 3].
As such, prevalent cases are included in both the numer-
ator and the denominator. When individual-level data are
available, the study population can be defined more pre-
cisely, usually in one of three ways: 1) persons with no pre-
vious diagnosis of the cancer subtype of interest, e.g., [4]; 2)
persons with no previous diagnosis of any cancer subtype
except non-melanoma skin cancer, e.g., [5]; and 3) persons
with no previous diagnosis of any cancer subtype, e.g., [6].
Moreover, individual-level data enable person-time to be
measured exactly. Variation in the precision of the numer-
ator and the denominator may cause incidence rates based
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on aggregate population data to deviate from incidence
rates based on individual-level data. However, the magni-
tude and direction of deviation between these methods is
unclear. It is essential to evaluate these differences as stan-
dardized incidence ratios, calculated to examine the effect
of an exposure or intervention in a subpopulation with
individual-level data, often depend on aggregate general
population statistics to estimate the expected number of
cases.
In studies of cancer incidence with individual-level
data, the choice of study population is important and
may influence the estimated incidence rate. For example,
if a cancer diagnosis is associated with higher incidence
of a second cancer subtype, then the incidence rate of
the second cancer subtype will be higher if persons with
a previous cancer diagnosis are included in the calcula-
tion than if they were excluded. However, the most ap-
propriate definition for the study population may not be
clear and depends on the research question at hand. For
descriptive purposes it would be prudent to include all
individuals with a new primary cancer diagnosis regard-
less of previous cancer diagnoses. However, for analytical
epidemiology, whether individuals with a previous can-
cer diagnosis should be included in the study population
depends on whether the previous cancer is considered
to be a confounder (i.e., associated with the exposure
and the second cancer of interest). For example, a previ-
ous cancer diagnosis may lead to changes in lifestyle or
behavior, while the treatment of a previous cancer can
affect future cancer risk. Cancer diagnostics and treat-
ments continue to improve, so the number of cancer
survivors at risk of a new cancer diagnosis continues to
increase [7]. It is therefore important to examine how the
definition of the study population influences estimates of
cancer incidence rates, particularly as variation in the
methods used to calculate cancer incidence rate may re-
duce comparability between studies. Although the extent
to which such methodological choices influence the over-
all incidence rate may have been examined within cancer
registries, to our knowledge this has not previously been
quantified in peer-reviewed scientific literature.
We aimed to evaluate the magnitude and direction of de-
viation between incidence rates calculated from aggregate
general population statistics and individual-level data. We
further aimed to assess the extent of differences in cancer
incidence rates calculated using three common definitions
of the study population in individual-level data. Although
we focus on cancer incidence rates, the principles of this
paper may also be relevant for other disease outcomes.
Methods
Study design
We conducted a population-based open cohort study of all
individuals officially resident in Sweden between January 1,
2000, and December 31, 2010. We used the Total Popula-
tion Register to identify the cohort and to ascertain age and
sex [8]. The cohort was linked to the Cancer Register and
the Cause of Death Register using the unique personal
identity number assigned to each individual registered in
Sweden [9]. All primary malignant cancer diagnoses be-
tween January 1, 1958, and December 31, 2010, were iden-
tified from the Cancer Register. The Cancer register has an
estimated completeness of at least 96%; however, it is not
considered complete before 1960 [10]. Aggregate general
population statistics on the mean annual population be-
tween 2000 and 2010 were retrieved from Statistics
Sweden. In the individual-level analyses, follow-up began
on January 1, 2000, and participants were censored on 1)
emigration before December 31, 2010, 2) death before De-
cember 31, 2010, or 3) end of study period, i.e., December
31, 2010. Ethical approval for the study was granted by the
Regional Ethical Review Board, Stockholm, Sweden (2011/
634-31/4).
Outcomes
We categorized cancer into 29 subtype groups in ac-
cordance with the cancer dictionary used in the World
Health Organization (WHO) cancer mortality database
[11]. Coding was based on the International Statistical
Classification of Diseases and Related Health Problems,
Seventh Revision (ICD-7), as this was available for the
whole period 1958–2010. The 29 cancer categories (and
corresponding ICD-10 codes) were lip, oral cavity and
pharynx (C00-C14); nasopharynx (C11); esophagus (C15);
stomach (C16); intestine (C17-C21); colon (C18); colon,
rectum, and anus (C18-C21); rectum and anus (C19-C21);
liver (specified as primary) (C22); gallbladder (C23-C24);
pancreas (C25); larynx (C32); lung (including trachea and
bronchus) (C33-C34); melanoma of skin (C43); breast
(C50, female only); uterus (C53-C55); cervix uteri (C53);
corpus uteri (C54); ovary (C56); prostate (C61); testis
(C62); kidney (C64); bladder (C67); brain and central ner-
vous system (C70-C72); thyroid (C73); Hodgkin lymph-
oma (C81); non-Hodgkin lymphoma (C82-C86, C96);
multiple myeloma (C88 + C90); and leukemia (C91-C95)
[11]. The four WHO categories, intestines (C17-C21),
colon (C18), colon, rectum, and anus (C18-C21), and rec-
tum and anus (C19-C21), are overlapping groups. All
groups were included for consistency with the classifica-
tion system. However, when discussed as a whole, these
groups will be referred to herein as colorectal cancer. Al-
though there were cases of male breast cancer, these were
not presented since there were very low numbers.
Statistical analysis
We calculated crude, age-standardized, and age-group-
specific (age groups: 0–24, 25–44, 45–64, 65–84, 85+
years) incidence rates for each cancer subtype, using
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four different methods (for further explanation see
Table 1):
1) Incidence rates calculated from aggregate general
population statistics, herein referred to as aggregate
population incidence rates. All new primary
malignant tumors recorded in the Cancer Register
during the study period were included. The person-
time at risk was estimated as the mean population
each year, summed over the study period. This replicates
the method used by cancer registries to calculate
incidence rates [2, 3].
2) Incidence rates calculated from individual-level data
with the study population defined as persons with
no previous subtype-specific cancer diagnosis, i.e.,
excluding individuals with a previous diagnosis of
the cancer subtype of interest, herein referred to as
subtype-specific incidence rates.
3) Incidence rates calculated from individual data with
the study population defined as persons with no
previous cancer diagnosis of any type except non-
melanoma skin cancer, i.e., excluding individuals
with any previous cancer diagnosis, except if the
previous cancer was non-melanoma skin cancer,
herein referred to as first cancer except non-melanoma
skin cancer incidence rates.
4) Incidence rates calculated from individual data with
the study population defined as persons with no
previous cancer diagnosis of any type, i.e., excluding
individuals with any previous cancer diagnosis, herein
referred to as first-ever cancer incidence rates.
Age-standardized incidence rates were calculated as
described by the International Agency for Research on
Cancer [3]. Incidence rates standardized to the world
standard population suggested by Segi 1960 and revised
by Doll et al., 1966 are presented in the results [3]. In
addition, incidence rates standardized to the Swedish
population in 2000 are provided in Additional File 1:
Table S1 [2].
We calculated incidence rate differences (IRD) and inci-
dence rate ratios (IRR) for each different method of calcu-
lating incidence rates. We used subtype-specific incidence
rates as the reference rates. As such, there are six compar-
isons (three IRD and three IRR) for each cancer subtype:
1) aggregate population incidence rates (any cancer diag-
nosis during the study period) vs. subtype-specific inci-
dence rates (first cancer of that subtype); 2) first cancer
except non-melanoma skin cancer incidence rates (first
cancer of any type, except non-melanoma skin cancer) vs.
subtype-specific incidence rates (first cancer of that sub-
type); and 3) first-ever cancer incidence rates (first cancer
Table 1 Four definitions of the study population applied to hypothetical data from seven patients
Year of diagnosis Number of breast cancer diagnoses counted for each
patient for each different definition of the study population
Prior to study period 1958–1999 Study period 2000–2010
Patient 1987 2002 2009 Aggra Subtypeb xNMSCc First everd
Ae Breast - - 0 0 0 0
Bf - Breast - 1 1 1 1
Cg NMSC Breast - 1 1 1 0
Dh Colon Breast - 1 1 0 0
Ei Breast Breast - 1 0 0 0
Fj - Breast Colon 1 1 1 1
Gk - Breast Breast 2 1 1 1
Cancer diagnoses prior to (1958–1999) and during (2000–2010) the study period, and number of breast cancer (BC) diagnoses counted using each definition of
the study population (SP)
aAggr, SP based on aggregate general population statistics
bSubtype, SP excluding individuals with a previous diagnosis of the cancer subtype of interest
cxNMSC, SP excluding individuals with any previous cancer diagnosis, except if the previous cancer was non-melanoma skin cancer
dFirst ever, SP excluding individuals with any previous cancer diagnosis
ePatient A: excluded from all methods as BC in 1987 was prior to the study period
fPatient B: counted in all methods as there was no previous cancer diagnosis before BC in 2002
gPatient C: BC in 2002 is counted in Aggr, Subtype and xNMSC, but not in First ever as the first ever cancer diagnosis was a non-melanoma skin cancer (NMSC)
in 1987
hPatient D: BC in 2002 is counted once in Aggr and once in Subtype, as it is the first subtype specific cancer. However, due to a previous colon cancer diagnosis
in 1987 BC in 2002 is not counted in xNMSC or First ever
IPatient E: BC in 2002 is counted once in Aggr. However, the patient is excluded from all other methods as the first BC occurred in 1987, which is not within the
study period
jPatient F: BC in 2002 is counted once in all methods (similar to patient B). The diagnosis of colon cancer in 2009 does not influence the incidence of BC
kPatient G: BC in 2002 and 2009 are counted as two cancers in Aggr, as there are two records of new primary tumours in the study period. However, only the BC
in 2002 is counted in the other methods as the first diagnosis
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of any type) vs. subtype-specific incidence rates (first can-
cer of that subtype).
Results
Cohort description
In total 10,515,591 individuals (49.7% males) were in-
cluded in the cohort. Based on aggregate population
data, a total of 99,799,233 years of person-time was ac-
cumulated, of which 29.8%, 26.9%, 25.9%, 15%, and 2.5%
was in the age groups 0–24, 25–44, 45–64, 65–84, and
85+ years, respectively. During the study period 476,719
new primary tumors, in mutually exclusive cancer sub-
types, were reported to the Cancer Registry. Based on
individual-level data, 459,174 of these tumors were diag-
nosed in persons with no previous subtype-specific can-
cer diagnosis, 410,428 were diagnosed in persons with
no previous cancer diagnosis of any type except non-
melanoma skin cancer, and 406,633 were diagnosed in
persons with no previous cancer diagnosis of any type.
Aggregate population incidence rates compared to
subtype-specific incidence rates
After age-standardization, aggregate population inci-
dence rates were ≥5% higher than subtype-specific inci-
dence rates for three cancer subtypes: lip, oral cavity,
and pharynx; breast (in women); and melanoma of skin
(Fig. 1 and Additional file 1: Table S1). The greatest dif-
ference was for breast cancer in women, for which age-
standardized aggregate population incidence rates were
8% higher than subtype-specific incidence rates (IRD:
10.5/100,000 person-years). However, age-standardized
aggregate population incidence rates were 6% lower than
subtype-specific incidence rates for prostate cancer
(IRD: -13.5/100,000 person-years) and 1% lower for cor-
pus uteri and uterus cancer (IRD: -0.3/100,000 person-
years) (Fig. 1 and Additional file 1: Table S1). We found
no difference between age-standardized aggregate popu-
lation incidence rates and subtype-specific incidence
rates in men and women for cancers of nasopharynx,
esophagus, stomach, liver, gallbladder, pancreas, and
ovary, or for Hodgkin lymphoma, and multiple myeloma
(Fig. 1 and Additional file 1: Table S1).
Age-group-specific incidence rates primarily followed the
patterns described above. The greatest absolute differences
between methods reflected age-specific peaks in incidence
rates (Fig. 2, Additional file 1: Tables S2 and S3). For ex-
ample, the greatest difference between methods for testicu-
lar cancer was in the 25–44 years age group, while for lung,
kidney, and breast cancers the greatest absolute difference
was in the 65–84 years age group. For the most part the
relative differences between aggregate population incidence
rates and subtype-specific incidence rates were rather stable
across age groups in both sexes (Fig. 3, Additional file 1:
Tables S2 and S3).
First cancer except non-melanoma skin cancer incidence
rates compared to subtype-specific incidence rates
Incidence rates were similar for first cancer except non-
melanoma skin cancer and first-ever cancer. As such,
first cancer except non-melanoma skin cancer incidence
rates compared to subtype-specific incidence rates re-
flect the results described below for first-ever cancer in-
cidence rates compared to subtype-specific incidence
rates.
First-ever cancer incidence rates compared to subtype-
specific incidence rates
Age-standardized first-ever cancer incidence rates were
≥5% lower than subtype-specific incidence rates for can-
cers of lip, oral cavity, and pharynx; esophagus (females);
lung, trachea, and bronchus (females); kidney; bladder
(females); and thyroid (males); and leukemia (females)
(Fig. 1 and Additional file 1: Table S1). Despite this, the
absolute difference in age-standardized incidence rates
was less than 5 cases per 100,000 person-years for all
subtypes (Fig. 1 and Additional file 1: Table S1).
Age-group-specific analyses indicated that, on an abso-
lute scale, first-ever cancer incidence rates were often
progressively lower than subtype-specific incidence rates
in the 45–64 and 65–85 years age groups. For some can-
cer subtypes, for example, Hodgkin lymphoma, uterus,
and breast cancers, this progression continued into the
oldest age group. For other cancer subtypes, for ex-
ample, lung and colorectal cancers, the absolute differ-
ence between these methods was reduced in the oldest
age group, or the pattern was reversed (Fig. 2, Additional
file 1: Tables S2 and S3). For most cancer subtypes the
relative difference between first-ever cancer incidence
rates and subtype-specific incidence rates across age
groups followed a similar pattern to the absolute differ-
ences (Fig. 3, Additional file 1: Tables S2 and S3).
Discussion
In a large population-based open cohort study, we high-
light several important methodological factors that
should be considered when calculating incidence rates.
First, we demonstrate notable differences between inci-
dence rates calculated from aggregate general population
statistics compared to those based on individual-level
data for some cancer subtypes. Second, we show that
cancer incidence rates calculated from individual-level data
vary depending on whether the study population includes
individuals with a previous cancer diagnosis. However, for
most cancer subtypes, these methods are broadly compar-
able. Although the results are only presented for Sweden in
the period 2000–2010, these main findings are likely to be
generalizable to other countries with similar social structure,
distribution of cancer type in the general population, and
cancer survival. Moreover, as social development results in
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Fig. 1 Age-standardized incidence rates (per 100,000 person-years) for 29 cancer subtypes. Incidence rates calculated using four different definitions of
the study population
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older populations and better cancer survival, the importance
of these methodological issues will become greater.
Strengths and limitations
The main strengths of this study were the very large
sample size and whole population coverage. The study
also had some limitations. First, 40% of individuals in-
cluded in the study were born before the cancer register
in Sweden started (1958). However, 96.8% of these per-
sons were younger than 40 years of age in 1958, so this
will have little effect on the results for the period 2000–
2010. In addition, we did not have information about can-
cer diagnoses before individuals immigrated to Sweden
because cancers are registered in the country of diagnosis.
However, the patterns of results were obtained when the
analysis was restricted to individuals born in Sweden
(Additional file 1: Table S4). In Sweden death-certificate-
only and death-certificate-initiated cancer cases are not
reported to the cancer register. However, since these data
will be missing for all methods of calculating incidence
rate, this underestimation will not impact the comparison
between methods. There may be more advanced ways to
correct the person-years at risk that were beyond the
scope of the current paper but should be kept in mind.
For example, excluding hysterectomized women from the
risk population in calculations of uterus cancer or chole-
cystectomized persons from the risk population in calcula-
tions of gallbladder cancer. Finally, basal cell carcinoma
has not been registered in Sweden so is one category of
cancer that was not possible to include in this paper.
Aggregate population incidence rates compared to
subtype-specific incidence rates
Aggregate population incidence rates were higher than
subtype-specific incidence rates for several cancer sub-
types. For cancer subtypes that showed this pattern, ex-
cluding individuals with a previous subtype-specific cancer
diagnosis from the study population reduced the numer-
ator to a greater extent than the denominator. This can be
explained if persons with a previous cancer diagnosis are
more likely to have a subsequent diagnosis of the same
cancer subtype than persons without a previous diagnosis
of that subtype. Supporting this, the difference between
these two methodologies was greatest for cancer subtypes
with a higher chance of a second primary cancer of the
same subtype, for example breast cancer in women [12]
and colorectal cancer [13].
For prostate cancer aggregate population incidence rates
were lower than subtype-specific incidence rates. As pros-
tate cancer has a low fatality level there were many preva-
lent cases in the aggregate population statistics that were
excluded when using individual-level data. As such, re-
moving those with a previous subtype-specific cancer
diagnosis reduced the denominator to a greater extent
than the numerator.
For highly fatal cancers, such as pancreas cancer, we
found no difference between aggregate population inci-
dence rates and subtype-specific incidence rates, as ex-
pected. This is because there were very few prevalent cases
to influence the denominator and a very low chance of a
second diagnosis of the same subtype.
Differences between aggregate population incidence
rates and subtype-specific incidence rates are important
for two reasons. First, in planning health service provision,
the use of aggregate population data is appropriate for
most cancer subtypes, even if they are overestimated com-
pared to individual-level data, as individuals with a second
primary tumor of the same subtype still need access to
health care despite their previous diagnosis. However,
when aggregate population data underestimate incidence
rates compared to individual-level data, there may be in-
adequate provision of services for individuals diagnosed
with these cancer subtypes. Nonetheless, besides incidence
rates health care planning is based on actual number of
cases, so this issue may be minimized. Second, the effect
of an exposure or intervention in a subpopulation with
individual-level data can be examined using standardized
incidence ratios. In such studies aggregate population sta-
tistics are often used to calculate the expected number of
cases. Different methodologies for calculating incidence
rates using the individual-level data compared to the ag-
gregate population data will results in distortion of the
standardized incidence ratios. In turn this may lead to im-
portant exposures being disregarded, while redundant in-
terventions may be deemed effective, or vice versa.
First-ever cancer, and first cancer except for non-
melanoma skin cancer incidence rates compared to
subtype-specific incidence rates
First-ever cancer, and first cancer except for non-
melanoma skin cancer incidence rates were often lower
than subtype-specific incidence rates. This can be ex-
plained since persons with a previous cancer diagnosis
are more likely to have a subsequent cancer diagnosis
than persons without a previous cancer diagnosis. For
(See figure on previous page.)
Fig. 2 Age-group-specific incidence rate differences (per 100,000 person-years) for 29 different cancer subtypes. Incidence rates calculated comparing
three different definitions of the study population (persons resident in Sweden, 1. based on general population statistics [Aggr pop]; 2. with no previous
cancer diagnosis except non-melanoma skin cancer [xNMSC]; and 3. with no previous cancer diagnosis of any type [First ever]) to incidence rates based
on a study population of persons resident in Sweden with no previous subtype-specific cancer diagnosis (Subtype)
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example, risk of subsequent neoplasm is raised in survi-
vors of childhood cancer [14], and in adults diagnosed
with first primary breast cancer (premenopausal), malig-
nant melanomas, bladder, and head and neck cancers
[15]. Increased risk of a second primary cancer may be re-
lated to ongoing surveillance of the patient leading to
greater detection, subsequent cancers may be linked etio-
logically including via shared behavioral and genetic risk
factors, and finally, treatment of the first malignancy may
increase the risk of subsequent disease. However, the ab-
solute difference between the methods for most cancer
subtypes was small, particularly for age-standardized inci-
dence rates. We therefore suggest that for most cancer
subtypes the comparability between studies using different
definitions of the study population is reasonable, especially
if age-standardized rates are presented.
When studying cancer subtypes with greater differ-
ences between methods, careful consideration should
be given to whether the previous cancer diagnosis is
likely to be a confounder. If there is no reason to be-
lieve that the previous cancer is a confounder, then
there is no reason to exclude individuals with a previ-
ous cancer. Our a priori hypothesis was that that
there might be larger differences between incidence
rates calculated with different study populations for
leukemia, due to the increased risk of leukemia after
treatment for a previous cancer subtype [16, 17].
However, there were not markedly greater differences
between methodologies for leukemia than for other
cancer subtypes. This indicates that persons with a
previous cancer diagnosis may be more likely to have
a subsequent cancer diagnosis than persons without a
previous cancer diagnosis due to shared risk factors,
rather than the previous cancer acting as a true con-
founder. As such, only excluding individuals with a
previous cancer of the same subtype may often be the
most appropriate way to define the study population.
This is of particular relevance for studies with limited
statistical power. Only excluding individuals with a
previous subtype-specific cancer diagnosis, rather than
all those with any previous cancer diagnosis, will in-
crease the number of cases available for analysis and
thus increase the statistical power.
Age-group-specific incidence rates
Relative differences between aggregate population inci-
dence rates and subtype-specific incidence rates were ra-
ther stable across age groups. In contrast, differences
between first-ever cancer incidence rates and subtype-
specific incidence rates varied by age group. The discus-
sion above could therefore have a lesser or greater
importance, depending on the age group being studied
and the cancer outcome of interest.
Conclusions
Cancer incidence rates vary depending on the defin-
ition of the study population. However, for most can-
cer subtypes, methods are broadly comparable when
age-standardized incidence rates are considered.
Nonetheless, when calculating cancer incidence rates
one should consider the purpose of the information,
the cancer outcome of interest, and the potential im-
precision the choice of the numerator and the de-
nominator might bring. This is particularly important
if standardized incidence ratios are calculated based
on general population statistics. The most appropriate
definition of the study population depends on etio-
logical arguments. However, defining the study popu-
lation as individuals with no previous subtype-specific
cancer diagnosis may be advantageous, particularly in
studies with limited statistical power.
Additional file
Additional file 1: Table S1. Crude and age-standardized incidence rates
(IR) (95% confidence intervals [95% CI]) per 100,000 person-years for 29
cancer subtypes in Swedish males and females between 2000 and 2010.
IRs were calculated using four definitions of the study population: per-
sons resident in Sweden 1) based on aggregate general population statis-
tics (Aggr); 2) with no previous subtype-specific cancer diagnosis
(subtype); 3) with no previous cancer diagnosis except non-melanoma
skin cancer (xNMSC); and 4) with no previous cancer diagnosis of any
type (First ever). IRs are presented with incidence rate differences (IRD)
and incidence rate ratios (IRR) compared to subtype-specific IRs (ref).
Table S2. Age-group-specific incidence rates (IR) (95% confidence intervals
[95% CI]) per 100,000 person-years for 25 cancer subtypes in Swedish
males between 2000 and 2010. IRs were calculated using four definitions of
the study population: persons resident in Sweden 1) based on aggregate
general population statistics (Aggr); 2) with no previous subtype-specific
cancer diagnosis (subtype); 3) with no previous cancer diagnosis except non-
melanoma skin cancer (xNMSC); and 4) with no previous cancer diagnosis of
any type (First ever). IRs are presented with incidence rate differences (IRD)
and incidence rate ratios (IRR) compared to subtype-specific IRs (ref). Table S3.
Age-group-specific incidence rates (IR) (95% confidence intervals [95% CI]) per
100,000 person-years for 27 cancer subtypes in Swedish females between
2000 and 2010. IRs were calculated using four definitions of the study
population: persons resident in Sweden 1) based on aggregate general
population statistics (Aggr); 2) with no previous subtype-specific cancer
diagnosis (subtype); 3) with no previous cancer diagnosis except non-
melanoma skin cancer (xNMSC); and 4) with no previous cancer diagnosis
of any type (First ever). IRs are presented with incidence rate differences
(IRD) and incidence rate ratios (IRR) compared to subtype-specific IRs (ref).
(See figure on previous page.)
Fig. 3 Age-group-specific incidence rate ratios for 29 different cancer subtypes. Incidence rates calculated comparing three different definitions of
the study population (persons resident in Sweden, 1. based on general population statistics [Aggr pop]; 2. with no previous cancer diagnosis
except non-melanoma skin cancer [xNMSC]; and 3. with no previous cancer diagnosis of any type [First ever]) to incidence rates based on a study
population of persons resident in Sweden with no previous subtype-specific cancer diagnosis (Subtype) for 29 different cancer subtypes
Brooke et al. Population Health Metrics  (2017) 15:2 Page 9 of 10
Table S4. Crude and age-standardized incidence rates (IR) (95% confidence
intervals [95% CI]) per 100,000 person-years for 29 cancer subtypes in
Swedish males and females between 2000 and 2010, including only
individuals born in Sweden. IRs were calculated using four definitions of the
study population: persons resident in Sweden 1) based on aggregate
general population statistics (Aggr); 2) with no previous subtype-specific
cancer diagnosis (subtype); 3) with no previous cancer diagnosis except
non-melanoma skin cancer (xNMSC); and 4) with no previous cancer
diagnosis of any type (First ever). IRs are presented with incidence rate
differences (IRD) and incidence rate ratios (IRR) compared to subtype-
specific IRs (ref). (DOCX 185 kb)
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